Both IAPPO-IgA (Figure 1E) and IAPPO-IgM (227.38 ± 83.37 vs. 205.37 ± 241.17, p = 0.023, respectively) levels were significantly higher in AD patients compared with NC in APOE4 non-carriers. This evidence concerns the gene CD79A and Alzheimer disease.